Summary In this study we investigated tumour growth in relation to the immunohistochemical expression of p53 and bcl-2 and to patient survival data in 33 operated hepatocellular carcinomas (HCCs). In order to estimate the growth, a growth index, based on the degree of cell proliferation, apoptosis and necrosis, was calculated for each tumour. Cell proliferation was determined immunohistochemically by the number of proliferating cell nuclear antigen (PCNA)-positive cells in tumours, the extent of apoptosis was determined by counting the number of cells labelled by the in situ 3'-end labelling technique and tumour necrosis was estimated as the percentage of necrotic areas in haematoxylin-eosin-stained tissue sections. In our analysis we found that the survival of patients with HCCs showing a high growth index (i.e. tumours showing a high proliferation and simultaneously a low degree of apoptosis and necrosis) was significantly shorter than with other patients (P= 0.004, log-rank test). When analysed separately, cell proliferation, apoptosis or necrosis did not show any significant association with survival. p53 positivity was found in 8/33 (24%) of tumours. There were significantly more p53-positive cases in tumours with a high growth index (P=0.01, Fisher's exact test) suggesting that dysfunction of the p53 gene may affect tumour growth. p53-positive cases did not, however, have a significantly shorter survival time than p53-negative cases (P=0.3, log-rank test). bcl-2 positivity was found in only 1/33 (3%) of the HCCs. Thus bcl-2 overexpression does not seem to play an important role in hepatocellular carcinogenesis. In summary, our results suggest that in HCCs a compound score based on the evaluation of the degree of cell proliferation, apoptosis and necrosis is a biologically more relevant prognostic indicator than any of its composite parameters alone.
The growth of a tumour depends on the proliferative capacity and destruction of the tumour cells (Reed, 1994) . Destruction of tumour cells can take place via apoptosis or necrosis. Characteristically, apoptosis is a biochemically highly regulated cell death that is often triggered by intrinsic mechanisms of the cell and typically involves scattered cells. Necrotic cell death, on the other hand, is due to environmental factors, such as loss of blood supply, which leads to a mass destruction of cells within a certain tumour area.
Apoptosis is regulated by several oncogenes and tumoursuppressor genes. An important group of genes regulating apoptosis are the bcl-2 gene family which includes bcl-2, bax, bcl-xL, bcl-xS, mcl-I and bad (Hockenberry, 1994; Reed, 1994) . They can either inhibit or promote apoptosis. bcl-2, for instance, inhibits while bax promotes apoptosis (Hockenberry, 1994; Reed, 1994; Miyashita and Reed, 1995) . Translocation of the bcl-2 gene in follicular lymphomas leads to an overexpression of bcl-2 protein and a decreased apoptosis (Tsujimoto et al., 1985) .
p53 is a tumour-suppressor gene that participates in DNA repair following DNA damage (Lane, 1992) . Upon DNA damage, p53 protein accumulates in the nucleus leading to a halt of the cell cycle at the G,-S boundary, which gives time for DNA repair to occur (Lane, 1992) . If the DNA repair fails, p53 will trigger apoptosis (Lane, 1992; Younish-Rouach et al., 1991) . Mutation of the p53 gene leads to loss of function which, in turn, leads to a genetic instability and neoplastic transformation (Lane, 1992) .
Mutations of the p53 gene are found in 38% of human malignant tumours (Greenblatt et al., 1994) . In hepatocellular carcinoma (HCC) p53 mutations are found in 25-50% of cases (Greenblatt et al., 1994) . There is a wide geographical variation in the incidence of p53 mutations in HCC that depend on the presence or absence of two major risk factors; dietary aflatoxin and hepatitis B and C infections (Greenblatt et al., 1994; Wands and Blum, 1991) . In Europe and North America, where both of these risk factors are low or nonexistent, the incidence of HCC is lower and p53 mutations in liver cancer occurs only in 10-25% of HCCs (Greenblatt et al., 1994; Volkmann et al., 1994) .
Morphological analysis of the degree and pattern of apoptosis and its relation to p53 expression and survival data in HCC has not so far been performed. In this study, we analysed the proliferative activity, apoptosis and necrosis in 33 HCCs removed at surgery and correlated the data with immunohistochemical expression of p53, bcl-2 and clinical data including, for example, survival of the patients. In order to estimate the net growth of the tumours, the proliferative activity, apoptosis and necrosis were scored separately and then combined to a single index that was compared with the other known parameters of the cases.
Materials and methods Materials
A total of 33 HCCs from the years 1983-93 were collected from the files of the Department of Pathology, Oulu University Central Hospital. The diagnosis of all cases was based on a conventional light microscopy according to the criteria of the World Health Organization (Gibson and Sobin, 1978 For p53 staining, the sections were first incubated overnight at 4°C with a polyclonal rabbit anti-human p53 antibody CM-1 (Novocastra Laboratories, Newcastle upon Tyne, UK) by using a dilution of 1:1000 (Soini et al., 1992) . This was followed by a biotinylated anti-rabbit immunoglobulin (dilution 1:100, Dakopatts) and the avidin-biotinperoxidase complex (Dakopatts).
For proliferating cell nuclear antigen (PCNA) staining, a mouse monoclonal IgG2a primary antibody was used (PC1O; Dako). The sections were incubated with the primary antibody (dilution 1:50) for 1 h followed by a secondary rabbit anti-mouse antibody (1:200) (Dakopatts) and the avidin -biotin-peroxidase complex (Dakopatts). Careful rinses were done with several changes of PBS between each stage of the procedure in all immunostainings.
For all the immunostainings, the colour was developed by diaminobenzidine, whereafter the sections were lightly counterstained with haematoxylin and mounted with Eukitt (Kindler, Freiburg, Germany).
Negative control stainings were carried out by substituting non-immune mouse or rabbit serum for the primary antibodies. As a positive control for bcl-2 and PCNA immunostaining, a lymph node with follicular hyperplasia was used. As a positive control for p53 immunostaining, we used sections from a lung carcinoma previously shown to be strongly positive for p53 (Soini et al., 1992) .
For bcl-2 and p53 stainings, the results were evaluated for positive (+) or negative (-) staining. For PCNA, the percentage of positively stained cells was evaluated in each section. bcl-2 immunostaining appeared as cytoplasmic while p53 and PCNA immunoreactivity was localised in the nuclei.
3'-End labelling of DNA in apoptotic cells To identify apoptotic cells, in situ labelling of the 3' ends of the DNA fragments generated by apoptosis-associated endonuclease was used. The 3'-end labelling of DNA was performed as previously described (T6rmanen et al., 1995 Assessment of apoptotic cells and apoptotic index Cells were defined as apoptotic if the whole nuclear area of the cell labelled positively (Figures 1 and 2 ). Apoptotic bodies were defined as small positively labelled globular bodies in the cytoplasm of the tumour cells that could be found either singly or in groups (Figure 1 ). The apoptotic index was defined as a sum of the apoptotic cells and bodies and it reflected the total number of apoptotic events in a given area. In cases in which many apoptotic bodies were found in a group but clearly located in one cell, the group of apoptotic bodies were counted as one (Figure 1 A combined index (growth index) was designed as follows; Growth index= 2 PCNA -(apoptosis score + necrosis score).
The indexes for each tumour obtained by this formula are given in Table I .
Statistical analysis
Comparisons between groups were made using the two-tailed Student's t-test. The significance of associations was determined using Fisher's exact probability test and correlation analysis.
The survival data were analysed according to the KaplanMeier method. The difference between survival in different groups was analysed using the log -rank, Breslow and Tarone -Ware test. Probability values less than 0.05 were considered significant. (Figures 3 and 4) . Positive nuclear p53 immunostaining was found in 8/33 (23%) HCCs and positive bcl-2 immunostaining only in 1/33 (3%) HCCs. In non-neoplastic hepatocytes, no p53 staining and bcl-2 expression was found. bcl-2 expression was, however, found in small proliferating bile ducts in association with cirrhosis and portal inflammation. Interestingly, PCNA-positive nonneoplastic hepatocytes were found in close proximity to the tumour areas, suggesting increased proliferation in these areas.
Apoptosis, mitosis and necrosis
The average relative number of apoptotic cells in HCCs was 0.28% (range 0.00-2.40%) and the average apoptotic index (apoptotic cells and apoptotic bodies combined) 0.73% (range 0.03-5.40%) (Figures 1 and 2) . The average relative number of apoptotic cells in non-neoplastic liver adjacent to the tumours was 0.04% (range 0.00-0.10%) and the average apoptotic index 0.10% (range 0.00-0.29%). As with PCNA there were more apoptotic cells and bodies in immediate proximity to the tumours. The average mitotic count in a b 
Survival analysis
The survival analysis was performed against the following variables; p53, PCNA, apoptotic index, necrosis, tumour size, chemotherapy treatment, stage and growth index. There was no significant difference in the patient survival between p53-positive and -negative cases (P=0.33, log-rank), high (>50% of cells positive) and low (<50% of cells positive) PCNA index (P = 0.27, log-rank) high and low apoptotic index (P=0.54, log-rank), high (>40%) or low (<40%) amount of necrosis (P = 0.52, log-rank) or large (> 10 cm) or small (<10 cm) tumour size (P = 0.30, log-rank). Patients receiving post-operative chemotherapy had a slightly shorter survival than other patients (P=0.20, log-rank). The patients with stage T3NOMO disease had a significantly shorter survival than those with stage T2NOMO or TINOMO (P=0.005, logrank; P = 0.0054, Breslow; P = 0.002, Tarone -Ware). In cases, in which the growth index was positive, the survival of the patients was significantly shorter than in those in which it was zero or negative (P= 0.004, log-rank; P= 0.006, Breslow; P = 0.004, Tarone -Ware) ( Figure 5 ). Also the disease-free interval after operation was significantly shorter in patients with stage T3NOMO disease (P=0.014, log-rank; P= 0.034, Breslow; P = 0.0022, Tarone-Ware) or positive growth index (P= 0.019, log-rank; P= 0.0039, Breslow; P= 0.005, Tarone-Ware). There was no statistically significant association between the growth index and TNM status (P=0.82, Fisher's exact test).
Analysis of tumour growth in relapsing HCCs
In 11 patients, it was possible to follow the growth of a relapsing tumour after the operation as in these patients Table I ). Generally, it is about the same as we have recently noticed in non-small-cell lung carcinoma, whereas small-cell lung carcinomas showed a higher degree of apoptosis (T6rmanen et al., 1995) . In nonsmall-cell lung carcinoma, increased apoptosis was associated with a shortened survival (T6rmanen et al., 1995) , an association which could not been found in HCCs, however. 100 120
Wild-type p53 has been shown to down-regulate the level of bcl-2 and up-regulate bax gene expression (Miyashita et al., 1994; Miyashita and Reed, 1995; Haldar et al., 1994 (Miyashita and Reed, 1995) . The frequency of p53 positivity in our material was about the same as has been previously described in HCC in European populations (Collier et al., 1994; Laurent-Puig et al., 1992; Volkmann et al., 1994) . p53 positivity in liver tumours was associated with a high proliferation index and also with a high growth index. This is as expected on the basis of the central role of p53 in the regulation of cell proliferation. Patients with p53-positive tumours had a shorter survival than p53-negative ones, but the association was not statistically significant.
We found only one HCC with an immunohistochemical expression of bcl-2. This is in line with a previous study showing no bcl-2 positivity in HCCs while considerable positivity was found in cholangiocarcinomas (Charlotte et al., 1994) . Our results thus show that expression of bcl-2 in HCCs is rare, but may occasionally be present. Interestingly, proliferating bile epithelial cells associated with liver cirrhosis or inflammation showed an increased expression of bcl-2.
Perhaps one associated mechanism for the increased number of bile ductules in these conditions (in association with a positive growth stimulus) is escape or protection of bile ductular epithelial cells from apoptosis.
Interestingly, an increased number of apoptotic cells was found among non-neoplastic hepatocytes adjacent to the tumour. Similarly, PCNA-positive cells were found in these areas. The finding suggests that tumour cells, perhaps through production of cytokines or growth factors, might stimulate apoptosis or cell proliferation in the adjacent nonneoplastic hepatocytes.
In conclusion, our results show that the capacity of tumour to grow (growth index as determined by PCNA, apoptosis and necrosis scoring) is associated with a shortened survival in operated HCCs. Evaluation of these parameters in tumours may be of value in assessing the prognosis of the disease.
